Lenalidomide/Revlimid - Brand Name or Equal
Veterans Affairs · 252-NETWORK CONTRACT OFFICE 12 (36C252)
Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.
Where this opportunity stands
Every notice posted under solicitation 36C25226Q0161 in this department, oldest first.
- Dec 18, 2025 · this noticeSolicitation
- Jan 16, 2026Award NoticeEXELAN PHARMACEUTICALS INC · $3.3MOpen
Next steps for this stage
Standard steps for the notice type; not advice about this buyer.
- Decide bid or no bid before the response deadline.
- Look at the past winners for likely competitors and teaming partners.
- Follow the opportunity to hear about amendments and the award.
What the notice says
This is for the purchase of Lenalidomide/Revlimid medication brand name or equal for the above facility Pharmacy Service. This requirement includes delivery/shipping to this FOB Destination: Edward Hines Jr VAMC, Hines, IL. See attached RFQ Solicitation document called, "S02_RFQ 36C25226Q0161_Stn578 Hines_Lenalidomide_due NLT 12.26.25 by 3PM CST" and refer to Section B for specific information. If interested or can provide the requested end-product and can meet the requirement, please submit all quotes NLT posting date listed to the POC, Contract Specialist via email only at: arneil.genus@va.g… (show all)
ov
Who won similar work
17 award notices on SAM.gov in the last 24 months. Matched by: Same office (252-NETWORK CONTRACT OFFICE 12 (36C252)), same product/service code (PSC) 6505 and NAICS 325412.
Single-winner award sizes (17): middle half $541K to $1.3M, median $787K; range $35K to $3.0M.
| Winner | Awards | Value | Last |
|---|---|---|---|
| EXELAN PHARMACEUTICALS INC | 6 | $11.9M | Jan 16, 2026 |
| PROGENICS PHARMACEUTICALS INC | 3 | $2.2M | Apr 22, 2026 |
| Bristol-Myers Squibb Company · $BMY · $49.2B | 1 | $848K | Jan 6, 2026 |
| VALNEVA USA, INC. | 1 | $787K | Oct 1, 2026 |
| JUBILANT DRAXIMAGE RADIOPHARMACIES, INC. | 1 | $740K | Feb 3, 2025 |
| Novartis Pharmaceuticals Corporation | 1 | $686K | Feb 11, 2026 |
| PHARMALOGIC HOLDINGS CORP. | 1 | $410K | May 5, 2025 |
| BOSTON SCIENTIFIC CORP · $BSX · $21.0B | 1 | $404K | Mar 26, 2025 |
| ON TARGET LABORATORIES, INC | 1 | $43K | Aug 5, 2025 |
| MEDI-PHYSICS, INC. | 1 | $35K | Jun 24, 2026 |
Value counts new single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling (same contract, or the same office, day and amount); that ceiling is not one company's win, so it is not added in. Contract modifications are not new awards and are not added in either. Revenue next to a ticker is the company's revenue over the latest 12 months in its SEC filings.
- $BMY reported $49.2B revenue (12 months to Jun 30, 2026). The median single-winner award in these 17 past awards, $787K, is under 0.1% of that. SEC filing
- $BSX reported $21.0B revenue (12 months to Jun 30, 2026). The median single-winner award in these 17 past awards, $787K, is under 0.1% of that. SEC filing
One award's total value against one year of revenue; many awards are paid over several years.
- Oct 1, 2026VALNEVA USA, INC.$787K6505--JAPANESE ENCEPHALITIS VIRUS VACCINE IXIARONo listed company matched (Materiality N/A)
- Jun 24, 2026MEDI-PHYSICS, INC.$35K6505--EMERGENCY DaTscan (Loflupane 123) InjectionNo listed company matched (Materiality N/A)
- Apr 22, 2026PROGENICS PHARMACEUTICALS INC$740K6505--PSMA Prostate Imaging Radiopharmaceuticals Base + 3 OYs 05/01/2026 - 04/30/2030No listed company matched (Materiality N/A)
- Feb 11, 2026Novartis Pharmaceuticals Corporation$686K6505--PluvictoNo listed company matched (Materiality N/A)
- Jan 16, 2026EXELAN PHARMACEUTICALS INC$1.3M6505--LENALIDOMIDE MEDICATIONNo listed company matched (Materiality N/A)
- Jan 6, 2026Bristol-Myers Squibb Company$848K6505--Revlimid, Pomalyst, Camzyos Specialty PharmaceuticalsMateriality: <0.01% of $BMY revenue (Low) SEC
- Dec 12, 2025EXELAN PHARMACEUTICALS INC$3.0M6505--LENALIDOMIDE Jesse Brown VA Medical CenterNo listed company matched (Materiality N/A)
- Dec 11, 2025EXELAN PHARMACEUTICALS INC$2.0M6505--Generic LenalidomideNo listed company matched (Materiality N/A)
- Dec 10, 2025EXELAN PHARMACEUTICALS INC$1.0M6505--Biologics by McKesson Specialty Pharmacy (Lenalidomide) (VA-26-00016920)No listed company matched (Materiality N/A)
- Dec 10, 2025EXELAN PHARMACEUTICALS INC$2.6M6505--Lenalidomide/Revlimid DoseNo listed company matched (Materiality N/A)
Materiality: one award's value as a share of the winner's revenue over the latest 12 months in its SEC filings (or its last fiscal year, as noted when you point at it). Low under 1%, Medium 1 to 5%, High 5% or more. Many awards are paid over several years, so this overstates a single year's share.
Competitive landscape
For the 8 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.
- 1 of these past winners lobbied Veterans Affairs, Dept of (VA) since 2024 (10 filings)
- 1 of their lobbyists list a past Veterans Affairs, Dept of (VA) job
- $45K from their corporate PACs since 2024 to members of House Committee on Appropriations, House Committee on Veterans' Affairs, Senate Committee on Appropriations, Senate Committee on Veterans' Affairs
- 0 foreign-agent (FARA) registrations
Policy around it
Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.
- 3 bills named on the past winners' lobbying filings
- 25 rules from the department in the last 12 months
- 0 executive orders naming the agency in the last 12 months
Market
For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.
- 2 of the past winners are listed companies
- 5 insider buys and 2 insider sells at them in the last 90 days
Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.
Companies are matched to tickers by exact name, including the subsidiaries a company lists in its SEC filings. A company we could not match shows no market rows; that is a miss, not a finding.